Armando OrlandiΒ· @ArmandOrlandi Β· XΒ·Β· 2 days agoScore70
Body
Cowabunga! π Riding the Metastatic Breast Cancer Wave ππ»ββοΈπ€π» from #ESMO26
APEX-Breast01: biparatopic HER2 antibody-drug conjugate TQB2102 vs chemo in HER2-low disease.
Progression-free survival 16.4 vs 5.5 mo.
New ADC, same ~0.3 hazard ratio. Time for head-to-head trials.
@OncoAlert @Larvol
294 views Β· 5 likes Β· 5 reposts Β· 0 replies
Conference abstracts
LBA27matched by Proffered paper 1: Breast cancer, early and advanced stage
APEX-Breast01: TQB2102 versus chemotherapy in HER2-low recurrent or metastatic breast cancer (r/m BC) - Results from a randomized phase 3 study
https://esmocongress.esmo.orgSource: Armando Orlandi Β· x.com